Entinostat and Lapatinib for HER2-Positive Advanced Disease

['lizbeth]

Entinostat and Lapatinib for HER2-Positive Advanced Disease

Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab (MDA-2010-0842)


NOTE: INDIVIDUALS WITH INFLAMMATORY BREAST CANCER (IBC) CAN PARTICIPATE IN ONLY THE PHASE I PORTION OF THE STUDY.
Summary

Researchers are looking for new ways to treat HER2+ tumors that do not respond or have stopped responding to the HER2-targeted therapy trastuzumab (Herceptin®). Entinostat is an investigational cancer drug that works by blocking protein enzymes called histone deacetylases (HDAC), which help cells divide. Lapatinib (Tykerb®) is a HER2-targeted therapy approved for the treatment of advanced breast cancer. Researchers are trying to determine the best dose and effectiveness of entinostat when it is given with Tykerb®. To be eligible, participants must have locally recurrent or metastatic HER2-positive disease, and have already been treated with Herceptin.
This is a Phase I-II trial

http://clinicaltrials.gov/show/NCT01434303